1 / 5

human papillomavirus (hpv) therapeutics

HPV Therapeutics Market is Forecast to Show Moderate Growth until 2017

rgunnam
Télécharger la présentation

human papillomavirus (hpv) therapeutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Human Papillomavirus (HPV) Therapeutics - PipelineAssessment and Market Forecasts to 2017

  2. HPV Therapeutics Market is Forecast to Show Moderate Growth until 2017 GlobalData estimates that the global HPV (human papillomavirus) therapeutics market was valued at $2.8 billion in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.0% over the next seven years, to reach $4.2 billion by 2017. This moderate growth rate is primarily attributed to a weak pipeline landscape. There are only 25 molecules in the pipeline and most of them are in the early stages of clinical development, so they are going to make an impact on the market after 2017. Moreover there is only one first-in-class molecules in Phase III, and that too is a prophylactic vaccine. Overall there is moderate growth in the HPV therapeutics market. A Need for Novel First-in-Class Drugs The HPV market is mainly dominated by prophylactic vaccines, which are only meant for those individuals who are not already infected with HPV infection. The prophylactic vaccine market has low unmet need, but still there is a need for first-in-class molecules that can fight against more HPV strains. The currently marketed vaccines are either bivalent or quadrivalent, so there is need for a multivalent vaccine in the prophylactic market. Apart from this, in the HPV therapeutics market the currently marketed products do not serve the unmet need. The unmet need is as high as 42%. As a result, there is a need for novel first-in-class molecules which offer better efficacy, safety and

  3. tolerability in the therapeutics market. The new molecule, with better qualities, could fulfill the HPV therapeutics market needs. The market continues to present opportunities for stronger pipeline candidates. Future Landscape of the HPV Market The current market landscape of the HPV prophylactic vaccines is declining because of the strong market and weak pipeline. The future landscape could change if any first-in-class vaccines enter the market and offer immunity against more strains of HPV. V503, a Phase III molecule, is expected to enter the market by 2014. As the existing vaccines in the market are either bivalent or quadrivalent, a multivalent molecule may change the future prophylactic market for HPV infection. However, in the case of the HPV therapeutics market, the landscape is expected to remain static, because the treatment of HPV relies on established older therapies such as cellular immune inducers and cytotoxic and anti-mitotic agents. The landscape is more likely to change in the near future if products with new mechanisms of actions such as DNA synthesis inhibitors and cysteine protease inactivators enter the market. However, currently these molecules are either in Phase II or the pre-clinical stage of development. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Human-Papillomavirus-HPV-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

  4. Weak Pipeline is Likely to Result in Moderate Growth for the HPV market. GlobalData analysis shows that the HPV therapeutics pipeline is weak, with 24 molecules in various phases of clinical development, including 13 first-in-class molecules. These first-in-class molecules are in the early stages of clinical development, so their impact on the market is expected to be after 2017. Moreover, there is only one first-in-class molecule in Phase II and that too is a prophylactic vaccine. In the case of HPV therapeutics, most of the late stage pipeline molecules do not have a novel mechanism of action. Thus the pipeline for the HPV therapeutics is weak and suggests moderate growth for the HPV market. GlobalData, the industry analysis specialist, has released its new report, “Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Human papillomavirus market. The report identifies the key trends shaping and driving the global Human papillomavirusmarket. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Human papillomavirus sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

  5. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Human-Papillomavirus-HPV-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017 Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782

More Related